psychedelics Archives

Psychedelic Trials Are Going Intravenous. Ketamine Clinics Already Have That Room

A new trial of intravenous psilocin points to where psychedelic delivery is heading. Ketamine clinics already have the infusion rooms and titration skills it needs.

Three Psychedelic Companies Analysts Say Could Be Acquired Next

The Deal That Changed the Temperature Eli Lilly agreed in July to pay up to $3.8 billion for AtaiBeckley. That number reset expectations across psychedelic medicine. Analysts now openly discuss which company gets bought next. For clinic owners, the question matters more than it might appear. The companies being courted are building the treatments your […]

Why Some Psychedelic Sessions Turn Frightening. A New Brain Study Offers a Clue

Most people who take a psychedelic under clinical supervision come through the session well. Some do not. A 2026 Stanford study in the Proceedings of the National Academy of Sciences offers a partial explanation for that difference. The clue sits in an unexpected place, namely the direction brain signals travel. Do you work in the […]

Nine of 12 Veterans Reached PTSD Remission After Psilocybin Therapy in Small Study

A small clinical trial found striking improvements among veterans with severe post traumatic stress disorder that had resisted standard care. Nine of 12 participants no longer met PTSD criteria one month after psilocybin assisted therapy. The result offers an important signal, but the study cannot prove that the treatment caused the improvement. Looking for treatment? Find Spravato clinics […]

Before a Buyer Calls: Getting Your Ketamine Clinic Ready for Acquisition

The first call rarely announces itself as an offer. It sounds like a compliment, someone building a platform in your region admires what you have built and wonders whether you have ever thought about partners. What happens next depends almost entirely on work you either did or did not do during the two years before […]

The First Ketamine Clinic Roll Ups Failed. The Next Wave Will Be Different

On July 16, Eli Lilly agreed to pay up to $3.8 billion for AtaiBeckley and its late stage psychedelic depression program. A week earlier, Johnson & Johnson reported $584 million in quarterly Spravato sales, up 40 percent in a year. AbbVie has already committed up to $1.2 billion for a psychedelic depression drug from Gilgamesh. […]

What a Ketamine Infusion Costs in 2026: Every Posted Price in Our Directory, Analyzed

The national median price of a ketamine infusion in 2026 is $400. That number comes from our own directory. We reviewed all 1,793 ketamine clinic listings on HealingMaps in July 2026, identified every clinic that publicly posts a treatment price, and verified 91 standard per session prices across 30 states. No survey, no estimates, no […]

What a Mindbloom Affiliated Study Can and Cannot Tell Us About At-Home Ketamine Injections

A study reports symptom improvement among patients in Mindbloom’s at-home ketamine injections. However, this was not an independent test.

North Carolina Lawmakers Push $5 Million Bill to Fund Psychedelic Therapy Research

North Carolina could become one of the first states in the South to fund psychedelic therapy research.

Eli Lilly Buys 5-MeO-DMT Developer AtaiBeckley for Up to $3.8 Billion, the Largest Psychedelic Deal Yet

Eli Lilly, the world’s largest pharmaceutical company, confirmed Thursday morning that it will acquire AtaiBeckley in a deal worth up to $3.8 billion. The purchase hands Lilly the company’s lead candidate, an intranasal form of 5-MeO-DMT for treatment resistant depression that is now entering Phase 3 trials. No acquisition in psychedelic medicine has come close […]